Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 18/20 | 0.79 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.79 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.79 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | CLK3 | P49761 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689238 | 0.89 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL18443882 | 0.89 | PIM1 (0.73) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18444344 | 0.88 | PIM1 (0.60) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18446933 | 0.87 | PIM1 (0.70) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18441003 | 0.87 | PIM1 (0.70) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18440546 | 0.86 | PIM1 (0.66) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18451970 | 0.86 | PIM1 (0.60) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18440213 | 0.86 | PIM1 (0.80) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18440255 | 0.85 | PIM1 (0.66) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL18440174 | 0.85 | PIM1 (0.71) | PIM1PIM2PIM3CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | claimed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | claimed |
| WO-2017023984-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | disclosed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | PIM1 1929/4885PIM2 1829/4885PIM3 1139/4885 |
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT3, WNT1, WNT3A | PIM1 1929/4885PIM2 1829/4885PIM3 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.